ANGLE plc (AGL.L)

14.62 +0.38 (+2.63%) At close: 05:05PM BST

ANGLE plc

Surrey Research Park
10 Nugent Road
Guildford GU2 7AF
United Kingdom
44 14 8334 3434
https://angleplc.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 150

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Andrew David William Newland ACA, Meng	Founder, CEO & Executive Director	281k	N/A	1961
Mr. Ian Francis Griffiths ACA, BA	CFO, Finance Director, Company Secretary & Executive Director	180k	N/A	1964
Mr. Martin Cooke	Director of Operations & Regulatory Affairs	N/A	N/A	1969
Dr. Karen Miller Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Andrew John Holder	Head of Investor Relations	N/A	N/A	1968
Ms. Anne-Sophie Pailhes-Jimenez	Head of R&D and Senior Director	N/A	N/A	N/A
Mr. Brett Swansiger	Chief Commercial Officer	N/A	N/A	N/A
Mr. Nick Claxton	Senior Vice President of Commercial Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Corporate governance

ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.